Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] CIL is engaged in trading of various nutritional health and sports supplement products. It posted growth in its top and bottom lines for the reported periods. However, boosted bottom lines from FY24 onwards raise eyebrows as it is operating in a highly competitive and fragmented segment. Based on its recent financial data, the issue appears fully priced. Well-informed/cash surplus investors may park moderate funds for long term. Read detail review...
Chemkart India IPO Reviews, analysis and views by popular members. Read Chemkart India Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
RHP